Treatment and prevention of osteoporosis

被引：9

作者：

Blahoš J. ^{[1
,2
]}

机构：

[1] Endocrine Unit and Osteocentre, Central Military Hospital, Prague

[2] Endorcine Unit and Osteocentre, Central Military Hospital, Klinická Endokrinologie a Osteocentrum, 169 02 Praha 6-Střešovice, ÚVN

来源：

Wiener Medizinische Wochenschrift | 2007年 / 157卷 / 23-24期

关键词：

Anabolics; Antiresorptives; Basic treatment; Future trends; Mixed effects; Osteoporosis;

D O I：

10.1007/s10354-007-0486-7

中图分类号：

学科分类号：

摘要：

Osteoporosis is recognized as a major health threat. The number of patients will certainly grow with the aging of the population. While preventive strategies, such as calcium, vitamin D, exercise and reduced risk factors may diminish the impact of menopause and age-regulated bone loss, many patients will become candidates for pharmacologic therapy. A variety of options are available, including HRT, bisphosphonates, SERMs, calcitonin, strontium ranelate, teriparatid. New forms of treatment are appearing on the horizon, such as monoclonal antibodies, nitrates, beta-blockers and Cathepsin K inhibitors. © Springer-Verlag 2007.

引用

页码：589 / 592

页数：3

共 4 条

[1]

Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.Y., Recker R.R., Hughes C., Lewiecki E.M., Felsenberg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C., Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study, J Bone Miner Res, 20, pp. 1315-1322, (2005)

[2]

Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R., HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of post-menopausal osteoporosis, N Engl J Med, 356, (1809)

[3]

Bilezikian J.P., Osteonecrosis of the jaw - do bisphosphonates pose a risk?, N Engl J Med, 355, pp. 2278-2281, (2006)

[4]

Marie P.J., Strontium ranelate: A dual mode of action rebalancing bone turnover in favour of bone formation, Curr Opin Rheumatol, 18, SUPPL. 1, (2006)

← 1 →